EML4 ‐ALK fusion variant V3 is a high‐risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK+ NSCLC

This article is protected by copyright. All rights reserved.

Source: International Journal of Cancer - January 24, 2018 Category: Cancer & Oncology Authors: Petros Christopoulos, Volker Endris, Farastuk Bozorgmehr, Mei Elsayed, Martina Kirchner, Jonas Ristau, Ivo Buchhalter, Roland Penzel, Felix J. Herth, Claus P. Heussel, Martin Eichhorn, Thomas Muley, Michael Meister, J ürgen R. Fischer, Stefan Rieken, Arn Tags: Research Article Source Type: research